These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 29896036)

  • 1. The International Liver Congress 2018.
    Alexander W
    P T; 2018 Jun; 43(6):362-366. PubMed ID: 29896036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. European Association for the Study of the Liver The International Liver Congress 2019.
    Alexander W
    P T; 2019 Jun; 44(6):365-369. PubMed ID: 31160873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver transplantation in patients with nonalcoholic steatohepatitis-related hepatocellular carcinoma.
    Malik SM; Gupte PA; de Vera ME; Ahmad J
    Clin Gastroenterol Hepatol; 2009 Jul; 7(7):800-6. PubMed ID: 19281869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential findings for CD14-positive hepatic monocytes/macrophages in primary biliary cirrhosis, chronic hepatitis C and nonalcoholic steatohepatitis.
    Leicester KL; Olynyk JK; Brunt EM; Britton RS; Bacon BR
    Liver Int; 2006 Jun; 26(5):559-65. PubMed ID: 16762000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are patients with cirrhotic stage primary sclerosing cholangitis at risk for the development of hepatocellular cancer?
    Harnois DM; Gores GJ; Ludwig J; Steers JL; LaRusso NF; Wiesner RH
    J Hepatol; 1997 Sep; 27(3):512-6. PubMed ID: 9314129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A report from The Liver Meeting 2014 (November 7-11 - Boston, Massachusetts, USA).
    Rabasseda X
    Drugs Today (Barc); 2014 Nov; 50(11):763-74. PubMed ID: 25525637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Familial occurrence of autoimmune liver disease with overlapping features of primary biliary cholangitis and autoimmune hepatitis in a mother and her daughter.
    Omori K; Yoshida K; Yokota M; Daa T; Kan M
    Clin J Gastroenterol; 2016 Oct; 9(5):312-8. PubMed ID: 27503128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A report from the European Association for the Study of the Liver's 50th International Liver Congress (April 22-26 - Vienna, Austria).
    Rabasseda X
    Drugs Today (Barc); 2015 Apr; 51(4):261-71. PubMed ID: 26020068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mouse models for investigating the underlying mechanisms of nonalcoholic steatohepatitis-derived hepatocellular carcinoma.
    Takakura K; Oikawa T; Tomita Y; Mizuno Y; Nakano M; Saeki C; Torisu Y; Saruta M
    World J Gastroenterol; 2018 May; 24(18):1989-1994. PubMed ID: 29760542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a novel mouse model of hepatocellular carcinoma with nonalcoholic steatohepatitis using a high-fat, choline-deficient diet and intraperitoneal injection of diethylnitrosamine.
    Kishida N; Matsuda S; Itano O; Shinoda M; Kitago M; Yagi H; Abe Y; Hibi T; Masugi Y; Aiura K; Sakamoto M; Kitagawa Y
    BMC Gastroenterol; 2016 Jun; 16(1):61. PubMed ID: 27296438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of using ursodeoxycholic acid to treat primary biliary cholangitis.
    Chapman RW
    Br J Hosp Med (Lond); 2018 Aug; 79(8):460-464. PubMed ID: 30070957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obesity and hepatocellular carcinoma.
    Caldwell SH; Crespo DM; Kang HS; Al-Osaimi AM
    Gastroenterology; 2004 Nov; 127(5 Suppl 1):S97-103. PubMed ID: 15508109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant nonalcoholic fatty liver disease does not alter the activity, severity or course of primary biliary cholangitis.
    Minuk GY; Iliant V; Zhou N; Kaita KD; Wong SG; Peretz D; Uhanova J
    Liver Int; 2018 Jun; 38(6):1110-1116. PubMed ID: 29193593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Nonalcoholic steatohepatitis: diagnosis, pathogenesis, treatment and prognosis].
    Jansen PL
    Ned Tijdschr Geneeskd; 2005 Feb; 149(6):289-94. PubMed ID: 15730035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hepatocellular carcinoma: occurrence, risk factors, biomarkers].
    Fehér J; Lengyel G
    Orv Hetil; 2010 Jun; 151(23):933-40. PubMed ID: 20494888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fulminant hepatitis in a patient with hepatocellular carcinoma related to nonalcoholic steatohepatitis treated with sorafenib.
    Brandi G; De Lorenzo S; Di Girolamo S; Bellentani S; Saccoccio G; Biasco G
    Tumori; 2015 Apr; 101(2):e46-8. PubMed ID: 25702656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of the toxic advanced glycation end-products-receptor axis in nonalcoholic steatohepatitis-related hepatocellular carcinoma.
    Takino J; Nagamine K; Hori T; Sakasai-Sakai A; Takeuchi M
    World J Hepatol; 2015 Oct; 7(23):2459-69. PubMed ID: 26483867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excellent posttransplant survival for patients with nonalcoholic steatohepatitis in the United States.
    Afzali A; Berry K; Ioannou GN
    Liver Transpl; 2012 Jan; 18(1):29-37. PubMed ID: 21932374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EASL International Liver Congress 2017.
    Alexander W
    P T; 2017 Jun; 42(6):398-401. PubMed ID: 28579728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatobiliary pathology.
    Lefkowitch JH
    Curr Opin Gastroenterol; 2008 May; 24(3):269-77. PubMed ID: 18408454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.